PharVision Advisers’s Crane Co CR Stock Holding History

PharVision Advisers’s Portfolio CR Stock Details CR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,214	Closed	-$224K	–	227
2025 Q4	$224K	Sell	1,214 -319	-21%	-$59.2K	0.11%	463
2025 Q3	$282K	Buy	+1,533	New	+$289K	0.16%	262

Other funds holding CR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PharVision Advisers's CR Position: Q1 2026 in Review

PharVision Advisers sold out of Crane Co (CR) in Q1 2026, closing a stake of 1,214 shares — an estimated $224K sold.

PharVision Advisers first reported a position in CR in Q3 2025 and held it in 2 quarters. The position peaked at $282K in Q3 2025. 560 funds tracked by Wall St. Rank hold CR as of Q1 2026.

PharVision Advisers reported no remaining Crane Co position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 1,214 Crane Co shares in Q1 2026, an estimated $224K.
PharVision Advisers first reported a position in Crane Co in Q3 2025 and held it in 2 quarters.
PharVision Advisers's Crane Co position peaked at $282K in Q3 2025.
560 funds tracked by Wall St. Rank held Crane Co as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.